Vanguard Group Inc Vaxcyte, Inc. Call Options Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PCVX
# of Institutions
268Shares Held
97.1MCall Options Held
202KPut Options Held
147K-
Black Rock Inc. New York, NY9.51MShares$724 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X07.67MShares$584 Million0.29% of portfolio
-
Wellington Management Group LLP Boston, MA4.92MShares$374 Million0.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.14MShares$315 Million0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.55MShares$270 Million0.15% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.51B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...